{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-037596","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.452227+00:00","generated_at":"2026-05-17T20:27:47.320552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit","bullets":["Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.","New U.S. patent (No. 12,377,104) covers Rezdiffra weight-threshold dosing; expires Feb 4, 2045 (previously Sept 30, 2044).","Licensed global rights to oral GLP-1 candidate SYH2086 from CSPC Pharma; enters clinic H1 2026 for MASH combination.","Secured $500M senior secured credit facility with Blue Owl: $350M initial term loan, $150M delayed draw, plus up to $250M incremental.","Positive CHMP opinion for Rezdiffra in Europe; EC decision expected Aug 2025; would be first MASH therapy in EU."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-037596","json":"https://secwatch.observer/filing/0001628280-25-037596.json","markdown":"https://secwatch.observer/filing/0001628280-25-037596.md","text":"https://secwatch.observer/filing/0001628280-25-037596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/0001628280-25-037596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/mdgl-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:27:47.320552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}